GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neogen Corp (FRA:NG2) » Definitions » Cyclically Adjusted Revenue per Share

Neogen (FRA:NG2) Cyclically Adjusted Revenue per Share : €4.17 (As of Feb. 2024)


View and export this data going back to 1989. Start your Free Trial

What is Neogen Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Neogen's adjusted revenue per share for the three months ended in Feb. 2024 was €0.979. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €4.17 for the trailing ten years ended in Feb. 2024.

During the past 12 months, Neogen's average Cyclically Adjusted Revenue Growth Rate was 6.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 12.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Neogen was 15.40% per year. The lowest was 2.70% per year. And the median was 13.10% per year.

As of today (2024-05-23), Neogen's current stock price is €12.10. Neogen's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2024 was €4.17. Neogen's Cyclically Adjusted PS Ratio of today is 2.90.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Neogen was 17.87. The lowest was 2.53. And the median was 10.63.


Neogen Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Neogen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neogen Cyclically Adjusted Revenue per Share Chart

Neogen Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.58 2.78 2.88 3.83 3.99

Neogen Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.28 3.99 4.08 4.05 4.17

Competitive Comparison of Neogen's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Neogen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neogen's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Neogen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Neogen's Cyclically Adjusted PS Ratio falls into.



Neogen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Neogen's adjusted Revenue per Share data for the three months ended in Feb. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=0.979/130.9299*130.9299
=0.979

Current CPI (Feb. 2024) = 130.9299.

Neogen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201405 0.488 100.373 0.637
201408 0.511 100.352 0.667
201411 0.551 99.635 0.724
201502 0.602 99.032 0.796
201505 0.702 100.333 0.916
201508 0.668 100.548 0.870
201511 0.735 100.135 0.961
201602 0.684 100.040 0.895
201605 0.787 101.355 1.017
201608 0.733 101.617 0.944
201611 0.824 101.829 1.059
201702 0.808 102.779 1.029
201705 0.845 103.256 1.071
201708 0.774 103.587 0.978
201711 0.826 104.072 1.039
201802 0.736 105.052 0.917
201805 0.870 106.148 1.073
201808 0.817 106.383 1.006
201811 0.896 106.338 1.103
201902 0.820 106.649 1.007
201905 0.937 108.048 1.135
201908 0.865 108.245 1.046
201911 0.923 108.519 1.114
202002 0.863 109.139 1.035
202005 0.942 108.175 1.140
202008 0.867 109.662 1.035
202011 0.911 109.793 1.086
202102 0.899 110.968 1.061
202105 0.969 113.576 1.117
202108 1.009 115.421 1.145
202111 1.057 117.269 1.180
202202 1.045 119.703 1.143
202205 1.229 123.323 1.305
202208 1.211 124.958 1.269
202211 1.044 125.607 1.088
202302 0.942 126.928 0.972
202305 1.027 128.314 1.048
202308 0.968 129.538 0.978
202311 0.980 129.548 0.990
202402 0.979 130.930 0.979

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Neogen  (FRA:NG2) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Neogen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=12.10/4.17
=2.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Neogen was 17.87. The lowest was 2.53. And the median was 10.63.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Neogen Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Neogen's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Neogen (FRA:NG2) Business Description

Industry
Traded in Other Exchanges
Address
620 Lesher Place, Lansing, MI, USA, 48912
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety (70% of post-merger sales), Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety (20% of post-merger sales), Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for 60% of total revenue, while international markets, including Canada, Europe, Asia, and Latin America, account for the remaining 40%.

Neogen (FRA:NG2) Headlines

No Headlines